<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604201</url>
  </required_header>
  <id_info>
    <org_study_id>080046</org_study_id>
    <secondary_id>08-H-0046</secondary_id>
    <nct_id>NCT00604201</nct_id>
    <nct_alias>NCT00608413</nct_alias>
  </id_info>
  <brief_title>Stem Cell Transplant Using Peripheral and Cord Blood Stem Cells to Treat Severe Aplastic Anemia and Myelopdysplastic Syndrome</brief_title>
  <official_title>Co-Infusion of Umbilical Cord Blood and Haploidentical CD34+ Cells Following Nonmyeloablative Conditioning as Treatment for Severe Aplastic Anemia and MDS Associated With Severe Neutropenia Refractory to Immunosuppressive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and effectiveness of treating patients with severe
      aplastic anemia (SAA) or myelopdysplastic syndrome (MDS) with both peripheral blood stem
      cells from a family member and umbilical cord blood stem cells from an unrelated donor.

      Patients with SAA or MDS for whom other treatments have failed or are not available may be
      eligible for this study. Candidates may not have a tissue-matched sibling or matched
      unrelated donor and must have a family member who is a partial tissue type match.

      Participants undergo the following tests and procedures:

        -  Insertion of a central intravenous (IV) line (plastic tube) into a large vein. The tube
           is used for giving the donated stem cells and antibiotics and other medicines, for
           transfusions of red blood cells and platelets, and for collecting blood samples.

        -  Preparatory chemotherapy (fludarabine, cyclophosphamide and anti-thymocyte globulin) and
           total body irradiation to suppress immunity and prevent rejection of the donated cells.

        -  Infusion of the donated stem cells and umbilical cord cells.

        -  Immune suppression with the drugs tacrolimus, mycophenolate mofetil and prednisone to
           prevent rejection of the donated cells and to prevent graft-versus-host disease (GVHD),
           a complication of stem cell transplants in which the donor s immune cells destroy the
           patient s healthy tissues.

      The average hospital stay after stem cell transplantation is 3 to 4 weeks. Patients return
      for frequent follow-up visits for the first 2 to 4 months after transplantation. Once the
      patient returns home, his or her referring physician is asked to send results of any
      laboratory testing to the NIH researchers at least every 3 months for the first 3 years and
      annually thereafter. Patient follow-up visits are scheduled at NIH at 1, 2, 3, 4 and 5 years
      after transplantation to monitor for signs of disease or post-transplantation complications,
      such as infection or GVHD. After 5 years, participants are offered the opportunity to enroll
      in NHLBI s long-term evaluation and follow-up care protocol.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe aplastic anemia (SAA) and myelodysplastic syndrome (MDS) are life-threatening bone
      marrow disorders. For SAA patients, long term survival can be achieved with immunosuppressive
      treatment. However, of those patients treated with immunosuppressive therapy, one quarter to
      one third will not respond, and about 50 percent of responders will relapse.

      Allogeneic bone marrow transplantation from either HLA-matched sibling or matched unrelated
      donor cures about 70 percent of patients with SAA and 30-60 percent of patients with MDS.
      Unfortunately, most patients with these disorders are not suitable candidates for
      hematopoietic stem cell transplantation (HSCT) due to advanced age or lack of a
      histocompatible donor. For such patients, transplantation using unrelated cord blood (UCB)
      has been shown to be a reasonable alternative transplant strategy. The advantage to UCB
      transplant is the ease and rapidity of availability, requirement of less than perfect HLA
      match, and lower rates of graft versus host disease compared to mismatched bone marrow or
      peripheral blood stem cell transplants. The major disadvantage of UCB transplantation in
      adults is the limited number of nucleated cells contained within the cord unit resulting in
      prolonged neutropenia and failure of engraftment which contributes to infection and
      transplant related mortality (TRM). In order to harness the advantage of UCB availability and
      to overcome the disadvantage of delayed neutrophil recovery, we propose to test whether
      co-administration of unrelated umbilical cord blood and a relatively low number of highly
      purified haploidentical peripheral blood CD34+ cells from a related donor might promote rapid
      engraftment and reduce TRM secondary to prolonged neutropenia associated with conventional
      UCBT.

      This research protocol is therefore designed to evaluate the safety and effectiveness of
      co-infusion of unrelated umbilical cord blood and haploidentical CD34 plus cells from a
      related donor following nonmyeloablative conditioning for neutropenic patients with SAA or
      MDS with refactory anemia (RA) that has proven to be refractory to medical therapy. Subjects
      will receive a novel non-myeloablative immunosuppressive conditioning regimen of
      cyclophosphamide, fludarabine, horse ATG and one dose of total body irradiation (200cGy)
      followed by an infusion of the allografts. The haploidentical stem cell product will be
      T-cell depleted and enriched for CD34 plus cells using the Miltenyi CliniMacs system. To
      reduce TRM secondary to prolonged neutropenia associated with conventional UCB
      transplantation, haploidentical CD34+ stem cells will be co-infused with a single UCB unit
      (serologically matched at greater than or equal to 4/6 HLA loci).

      The primary endpoint is donor engraftment by day 42 (defined as an ANC of greater than 500
      from either the haplo donor, the cord, or both combined). Secondary endpoints will include
      standard transplant outcome variables such as non-hematological toxicities, incidence and
      severity of acute and chronic GVHD, and relapse of disease. We will also evaluate ANC
      recovery (ANC greater than 500 cells/microl) at day 22, and 100 day and 200 day treatment
      related mortality (TRM) of this novel transplant approach. Health related quality of life
      will also be assessed pre-transplant 30 and 100 days poste transplant, and every 6 months
      until 5 years post transplant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 7, 2008</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 42 cord engraftment</measure>
    <time_frame>Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>200 day treatment related mortality (TRM) and standard transplant outcome variables (non-hematological toxicities, incidence and severity of acute and chronic GVHD, and relapse of disease)</measure>
    <time_frame>Day 200</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <condition>Severe Aplastic Anemia (SAA)</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Umbilical Cord Blood</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Haploidentical Stem Cells</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Miltenvi CliniMACs CD34 Reagent System</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA - RECIPIENT:

          -  Diagnosed with severe aplastic anemia characterized by all of the following:

               1. Bone marrow cellularity less than 30 percent (excluding lymphocytes)

               2. Transfusion dependence for platelets and/or RBCs

               3. Neutropenia (absolute neutrophil count less than 500 cells/microL) OR for
                  patients receiving granulocyte transfusions, absolute neutrophil count &lt; 500
                  cells/microL before beginning granulocyte transfusions].)

        OR

          -  Diagnosed with myelodysplastic syndrome characterized by refractory anemia OR
             refractory anemia with ringed sideroblasts (RARS and at least one of the following:

               1. Neutropenia [(absolute neutrophil count &lt; 500 cells/microL) OR for patients
                  receiving granulocyte transfusions, absolute neutrophil count &lt; 500 cells/microL
                  before beginning granulocyte transfusions]) and history of 1 or more
                  opportunistic infections related to neutropenia. OR

               2. History of severe aplastic anemia transformed to MDS

          -  Intolerance of or failure to respond standard immunosuppressive therapy.

          -  Availability of at least one HLA-haploidentical (i.e. greater than or equal to 5/10
             and less than or equal to 8/10 HLA match) related donor (HLA-A, B, C, DR, and DO loci)
             who is available to donate CD34+ cells (4-75 years old).

          -  Availability of at least one 4/6 HLA-matched (HLA-A, B, and DR loci) cord blood unit
             from the National Marrow Donor Program (NMDP). The cord blood unit must contain a
             minimum TNC (prior to thawing) of at least 1.5 x 10(7) cells per kilogram of recipient
             body weight with the following exception: if the minimum criterion of TNC is not met
             the cord unit must contain at least 1.7 x 10(5) CD34 plus cells/kg (prior to thawing).

          -  Ages 4-55 years inclusive.

          -  Ability to comprehend the investigational nature of the study and provide informed
             consent. The procedure will be explained to subjects aged 4-17 years with formal
             consent being obtained from parents or legal guardian.

               -  Telomere Length Testing

               -  In patients where a suspicion for a familial bone marrow failiure syndromes
                  (BMFS) exists, TERC and TERT mutation testing will be performed on protocol
                  04-H-0012 or performed elsewhere prior to enrolling on 04-H-0012.

        EXCLUSION CRITERIA - RECIPIENT:

          -  Availability of an HLA identical or 9/10 HLA matched(HLA A, B, C, DR, and DO
             loci-relative to serve as a stem cell donor.

          -  The patient is deemed to be a candidate for a 6/6 HLA matched unrelated stem cell
             transplant (availability of a donor and resources required for such a transplant).

          -  ECOG performance status of 2 or more.

          -  Major anticipated illness or organ failure incompatible with survival from transplant

          -  Severe psychiatric illness. Mental deficiency sufficiently severe as to make
             compliance with the transplant treatment unlikely and making informed consent
             impossible.

          -  Positive pregnancy test for women of childbearing age.

          -  HIV positive

          -  Diagnosis of Fanconi's anemia (by chromosome breakage study).

          -  Diffusion capacity of carbon monoxide (DLCO) less than 40 percent using DLCO corrected
             for Hgb or lung volumes (patients under the age of 10 may be excluded from this
             criterion if they have difficulty performing the test correctly and thus are unable to
             have their DLCO assessed).

          -  Left ventricular ejection fraction less than 40 percent (evaluated by ECHO) or less
             than 30 percent (evaluated by MUGA)

          -  Transaminases greater than 5x upper limit of normal (when transaminases are elevated,
             the subject may be excluded at the discretion of the PI).

          -  Serum bilirubin greater than 4 mg/dl

          -  Creatinine clearance less than 50 cc/min by 24 hr urine collection (adjusted for body
             surface area, i.e.50 ml/min/1.73m(2))

          -  Serum creatinine &gt; 2.5 mg/dl

          -  Failure to collect an adequate number of CD34+ cells (i.e. greater than or equal 2 x
             10(6) CD34+ cells/kg) for transplantation from the subject s haploidentical relative.

          -  Presence of an active infection not adequately responding to appropriate therapy

          -  History of a malignant disease liable to relapse or progress within 5 years

        INCLUSION CRITERIA - RELATED HAPLOIDENTICAL DONOR DONATING PURIFIED CD34 PLUS CELLS:

          -  HLA mismatched family donor (greater than or equal to 5/10 and less than or eqhal to
             8/10 HLA matched (HLA-A, B, C, DR and DO loci) who is available to donate CD34+ cells.

          -  Ages 4-75 inclusive

          -  Weight greater than or equal to 15 kg.

          -  For adults: Ability to comprehend the investigational nature of the study and provide
             informed consent. For minors: Written informed consent from one parent or guardian who
             is not the recipient of the transplant and informed assent: The process will be
             explained to the minor on a level of complexity appropriate for their age and ability
             to comprehend.

          -  If there is a suspicion of familial BMFS in the recipient, then the donor must have
             undergone genetic testing for genes associated with BMFS - performed at a
             CLIA-certified laboratory, prior to enrollin in this protocol.

        EXCLUSION CRITERIA RELATED DONOR (ANY OF THE FOLLOWING):

          -  Pregnant or breastfeeding.

          -  A pediatric haploidentical donor will be excluded if a suitable adult haploidentical
             donor is available.

          -  Unfit to receive filgrastim (G-CSF) and undergo apheresis (history of stroke, MI,
             unstable angina, uncontrolled hypertension, severe heart disease or palpable spleen).

          -  HIV positive (Donors who are positive for HBV, HCV or HTLV I/II, T. cruzi [Chagas] may
             be used at the discretion of the investigator following counseling and approval from
             the recipient).

          -  Sickling hemoglobinopathies including HbSS, HbAS, HbSC

          -  Severe psychiatric illness. Mental deficiency sufficiently severe as to make
             compliance with the BMT treatment unlikely and making informed consent impossible.

          -  Screening test positive for Chagas disease (Trypanosoma cruzi /T.
             cruzi/trypanosomiasis) confirmed by the Center for Disease Control (CDC).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard W Childs, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tatyana Worthy, R.N.</last_name>
    <phone>(301) 594-8013</phone>
    <email>worthyt@mail.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)</last_name>
      <phone>800-411-1222</phone>
      <phone_ext>TTY8664111010</phone_ext>
      <email>prpl@cc.nih.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2008-H-0046.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Young NS, Barrett AJ. The treatment of severe acquired aplastic anemia. Blood. 1995 Jun 15;85(12):3367-77. Review.</citation>
    <PMID>7780125</PMID>
  </reference>
  <reference>
    <citation>Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997 May 8;336(19):1365-72. Review.</citation>
    <PMID>9134878</PMID>
  </reference>
  <reference>
    <citation>Zoumbos NC, Gasc√≥n P, Djeu JY, Trost SR, Young NS. Circulating activated suppressor T lymphocytes in aplastic anemia. N Engl J Med. 1985 Jan 31;312(5):257-65.</citation>
    <PMID>2981406</PMID>
  </reference>
  <verification_date>April 30, 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2008</study_first_submitted>
  <study_first_submitted_qc>January 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodyplastic Syndrome (MDS)</keyword>
  <keyword>Severe Aplastic Anemia (SAA)</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Haploidentical Stem Cells</keyword>
  <keyword>Umbilical Cord Blood</keyword>
  <keyword>Severe Aplastic Anemia</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

